Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated

Vanda Pharmaceuticals Inc. announced that its Phase III clinical study of VQW-765 for treating social anxiety disorder did not meet its primary endpoint. However, the drug was reported to be safe and well tolerated, consistent with previous studies. The study, designated VP-VQW-765-3201, focused on the on-demand treatment of acute anxiety in adults.